Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

22.7%

5 terminated/withdrawn out of 22 trials

Success Rate

77.3%

-9.2% vs industry average

Late-Stage Pipeline

14%

3 trials in Phase 3/4

Results Transparency

71%

12 of 17 completed trials have results

Key Signals

12 with results

Enrollment Performance

Analytics

Phase 2
10(47.6%)
Phase 1
7(33.3%)
Phase 3
2(9.5%)
Phase 4
1(4.8%)
Early Phase 1
1(4.8%)
21Total
Phase 2(10)
Phase 1(7)
Phase 3(2)
Phase 4(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT02688647Phase 2Completed

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

Role: lead

NCT02317627Phase 2Completed

Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy

Role: lead

NCT03907540Phase 1Completed

Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025

Role: lead

NCT03530995Phase 1Completed

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Role: lead

NCT02557139Phase 1Completed

Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

Role: lead

NCT02616055Phase 2Terminated

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Role: lead

NCT00336765Phase 1Completed

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Role: lead

NCT00522145Phase 2Completed

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Role: lead

NCT00364780Phase 2Completed

Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

Role: lead

NCT01487174Phase 3Terminated

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Role: lead

NCT00086528Phase 1Completed

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Role: lead

NCT03096080Phase 1Completed

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Role: lead

NCT04735822Early Phase 1Completed

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Role: lead

NCT02154529Phase 1Terminated

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Role: lead

NCT02106195Phase 2Completed

A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris

Role: lead

NCT02616393Phase 2Completed

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Role: lead

NCT02852967Phase 2Completed

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

Role: lead

NCT02844439Phase 2Completed

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Role: lead

NCT00730158Phase 2Completed

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

Role: collaborator

NCT00951223Withdrawn

Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C

Role: lead